{"entity":{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","aka":[],"tldr":"Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment.","summary":"Kirsten Fischer was principal investigator of CLL14, the German CLL Study Group trial showing twelve months of venetoclax plus obinutuzumab produces deep, MRD-negative remissions and superior progression-free survival compared with chlorambucil-obinutuzumab in unfit patients with untreated CLL, creating the fixed-duration treatment paradigm. She coordinated the CLL8 and CLL10 chemoimmunotherapy trials and leads long-term follow-up of CLL14.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fischer%20K%5BAuthor%5D%20CLL14%20venetoclax"}],"tags":["cll","venetoclax","fixed-duration"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2","cd20"],"drugs":["venetoclax"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["cll14"],"people":[],"bottlenecks":[],"keyPapers":["paper-cll14-venetoclax-obinutuzumab-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Physician and Study Coordinator, German CLL Study Group, University Hospital Cologne","institutionId":"uniklinik-koeln","specialisms":["Chronic lymphocytic leukaemia","Fixed-duration therapy","Venetoclax combinations","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fischer%20K%5BAuthor%5D%20CLL14%20venetoclax"}],"papers":[{"title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1815281"},{"title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30443-5"}]},"route":"/people/kirsten-fischer/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"trial":[{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/"}],"paper":[{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/"}]}}